← Back to Search

Anti-diabetic agent

Glipizide for High Blood Sugar in Pancreatic Cancer

Phase 2

Recruiting

Led By James Flory, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Cohort 2b: History of distal pancreatectomy or of Whipple surgery, Greater than trace ascites documented on imaging or physical exam

Cohort 2a: History of distal pancreatectomy or of Whipple surgery, Greater than trace ascites documented on imaging or physical exam

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 48 hours after glipizide initiation

Awards & highlights

No Placebo-Only Group

Summary

This trial tests if glipizide is a safe and effective way to lower blood sugar in people with pancreatic cancer. #medicine

Who is the study for?

This trial is for adults over 18 with metastatic pancreatic cancer and high blood sugar levels, who haven't had certain diabetes treatments or surgeries like Whipple surgery. They should be able to use a mobile device with Bluetooth and follow the study's protocol. People are excluded if they have a history of severe hypoglycemia, certain liver issues, very low kidney function, significant fluid in the abdomen, or daily steroid use.

What is being tested?

The trial is testing how well Glipizide can lower blood sugar in people with advanced pancreatic cancer. It aims to determine both the effectiveness and safety of this medication specifically for these patients.

What are the potential side effects?

Glipizide may cause side effects such as low blood sugar (hypoglycemia), which can lead to symptoms like dizziness, sweating, hunger, irritability or mood changes. Other possible side effects include skin reactions at injection sites and digestive issues.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have had surgery on my pancreas and have more than a small amount of fluid in my abdomen.

Select...

I have had surgery on my pancreas and have more than a small amount of fluid in my abdomen.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 48 hours after glipizide initiation

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~48 hours after glipizide initiation

This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 hours after glipizide initiation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in mean interstitial glucose level for Cohort 1 participants before and after initiation of glipizide

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Cohort 1Experimental Treatment1 Intervention

Participants in this cohort will receive glipizide for up to 4 months and participate in continuous glucose monitoring for as long as they are receiving the drug.

Group II: Cohort 2aActive Control1 Intervention

Participants in this cohort will include people who have received various types of treatment for their hyperglycemia and pancreatic cancer. People's medical records will be reviewed to compare the effects of glipizide with the effects of other standard medications used to treat hyperglycemia.

Group III: Cohort 2bActive Control1 Intervention

Participants in this cohort will complete a questionnaire about their use of hyperglycemia medications. Participants from Cohort 2a will take part in this group.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Glipizide

2007

Completed Phase 4

~6180

0 / 2Eligibility criteria met